TD Private Client Wealth LLC cut its holdings in Chemed Co. (NYSE:CHE – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,835 shares of the company’s stock after selling 41 shares during the quarter. TD Private Client Wealth LLC’s holdings in Chemed were worth $1,502,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of CHE. Raymond James Financial Inc. purchased a new stake in shares of Chemed in the fourth quarter valued at approximately $42,023,000. FMR LLC boosted its stake in shares of Chemed by 23.8% in the third quarter. FMR LLC now owns 238,616 shares of the company’s stock valued at $143,401,000 after buying an additional 45,917 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Chemed by 114.1% in the fourth quarter. Principal Financial Group Inc. now owns 74,658 shares of the company’s stock valued at $39,554,000 after buying an additional 39,791 shares in the last quarter. Aureus Asset Management LLC boosted its stake in shares of Chemed by 3,147.2% in the third quarter. Aureus Asset Management LLC now owns 29,939 shares of the company’s stock valued at $17,993,000 after buying an additional 29,017 shares in the last quarter. Finally, Boston Trust Walden Corp boosted its stake in shares of Chemed by 10.0% in the fourth quarter. Boston Trust Walden Corp now owns 242,172 shares of the company’s stock valued at $128,303,000 after buying an additional 22,105 shares in the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Chemed
In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $593.67, for a total transaction of $1,187,340.00. Following the completion of the sale, the chief executive officer now directly owns 102,679 shares in the company, valued at $60,957,441.93. This represents a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Brian C. Judkins purchased 145 shares of the company’s stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $519.50 per share, with a total value of $75,327.50. Following the completion of the purchase, the vice president now directly owns 1,678 shares of the company’s stock, valued at $871,721. The trade was a 9.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.32% of the company’s stock.
Chemed Stock Down 1.2 %
Chemed Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Monday, February 24th were paid a $0.50 dividend. The ex-dividend date was Monday, February 24th. This represents a $2.00 annualized dividend and a yield of 0.34%. Chemed’s payout ratio is currently 10.05%.
Analyst Ratings Changes
CHE has been the topic of a number of research analyst reports. StockNews.com upgraded Chemed from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Royal Bank of Canada boosted their price target on Chemed from $633.00 to $667.00 and gave the stock an “outperform” rating in a report on Friday, March 14th.
Check Out Our Latest Stock Report on CHE
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
- Five stocks we like better than Chemed
- What is Insider Trading? What You Can Learn from Insider Trading
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Why Are Stock Sectors Important to Successful Investing?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What Investors Need to Know to Beat the Market
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.